Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Wendy L. Carofano"'
Autor:
Raymond L. H. Lam, Julio Rosenstock, Wendy L. Carofano, Roy Eldor, Gregory T. Golm, Philip Home, Baptist Gallwitz, Michael C. Marcos, Priscilla Hollander, Michael F. Crutchlow
Publikováno v:
Diabetes, Obesity and Metabolism. 20:2220-2228
Aim To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM). Materials and methods This phase 3, randomized, active-controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58ff53d3128cdeebf56d91c4bad422c
https://doi.org/10.1111/dom.13354
https://doi.org/10.1111/dom.13354
Autor:
Gregory T. Golm, Roy Eldor, Wendy L. Carofano, Priscilla Hollander, Raymond L. H. Lam, Baptist Gallwitz, Julio Rosenstock, Michael F. Crutchlow, Marc Rendell, Philip Home, Michael C. Marcos
Publikováno v:
Diabetes, obesitymetabolism. 20(9)
Aim To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM). Materials and methods This Phase 3, randomized, active-controlled, open-label, 24-week clinical trial (Cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96a8b328630c8bc2c369cf6bebca094
https://pubmed.ncbi.nlm.nih.gov/29761615
https://pubmed.ncbi.nlm.nih.gov/29761615
Autor:
Keith D. Kaufman, Ngozi Erondu, Amy O. Johnson-Levonas, Søren Toubro, Shailaja Suryawanshi, Menghui Chen, Deborah R. Shapiro, John M. Amatruda, Ira Gantz, Wendy L. Carofano, Thomas A. Wadden, Ken Fujioka, Steven B. Heymsfield
Publikováno v:
Obesity. 18:2301-2310
Improving the maintenance of weight loss remains a critical challenge for obesity researchers. The present 1-year, randomized, placebo-controlled trial evaluated the safety and efficacy of weight maintenance counseling combined with either placebo or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f1d177fde8b6a800b34941a5945a20
https://doi.org/10.1038/oby.2010.67
https://doi.org/10.1038/oby.2010.67
Autor:
Joel A. Block, Kerry Siminoski, Michelle Czachur, Charles J. Menkes, Harris H. McIlwain, Pierre D. Delmas, Jeffrey Wing, Jean-Marc Kaufman, Melissa J. Yanover, Federico Hawkins, Michael C. Nevitt, Uri A. Liberman, Thomas Dumortier, Ricardo Correa-Rotter, Barry L. Gruber, Ronald Emkey, M O R Leite, John T. Sharp, Patrice E. Poubelle, Rene Westhovens, Ego Seeman, Jacques P. Brown, Marie Pierre Malice, Nancy E Lane, Daifotis Anastasia G, Thomas J. Schnitzer, Jonathan D. Adachi, J Melo-Gomes, Kenneth G. Saag, Wendy L. Carofano, Jose Adolfo Rodriguez-Portales
Publikováno v:
Arthritis & Rheumatism. 44:202-211
OBJECTIVE: To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids. METHODS: This is a 12-month extension of a previously completed 1-year trial of daily ALN, performed to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d924ccb0db1773da50135b722347391
https://doi.org/10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co
https://doi.org/10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co